Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 40Carcinoma, Non-Small-Cell Lung 22Head and Neck Neoplasms 20Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Glioma 11Lung Neoplasms 8Carcinoma, Squamous Cell 8Breast Neoplasms 8Astrocytoma 8Rectal Neoplasms 7Neoplasms 7Prostatic Neoplasms 6Mucositis 5Esophageal Neoplasms 5Carcinoma 4Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Xerostomia 2Stomatitis 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neoplasms, Squamous Cell 2Lymphoma 2Leukemia 2Laryngeal Diseases 2Gliosarcoma 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2

Interventions

osimertinib 1itacitinib 1Radiotherapy 1INCB039110 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Inhibition, Psychological × Radiotherapy × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡